+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multicancer Screening Market - Global Forecast 2026-2032- Product Image
Multicancer Screening Market - Global Forecast 2026-2032- Product Image
New

Multicancer Screening Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5925117
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The multicancer screening market is entering a phase of rapid evolution, where innovation in diagnostics, shifting clinical standards, and advancing regulatory trends are reshaping how leaders in healthcare, research, and industry approach detection and patient management. Staying ahead requires continuous adaptation to new technologies, operational realities, and reimbursement models.

Market Snapshot: Multicancer Screening Market Growth

The global multicancer screening market grew from USD 630.87 million in 2025 to USD 822.84 million in 2026 and is projected to reach USD 4.37 billion by 2032, reflecting a Compound Annual Growth Rate (CAGR) of 31.87%. This robust expansion highlights strong investor confidence in next-generation tumor signal detection, as well as increasing reliance on genomics and proteomics to enhance oncology diagnostics. Parallel advancements in workflow integration and broader clinical adoption continue to fuel demand. Senior stakeholders are responding by prioritizing early detection and comprehensive screening strategies capable of targeting varied cancer types within streamlined care pathways.

Scope & Segmentation

This research offers a detailed analysis of the multicancer screening ecosystem with emphasis on emerging technologies, clinical implementation, changing procurement frameworks, and policy-driven shifts across major markets. The report reviews how technology uptake, local payer environments, and infrastructure shape the commercial landscape and opportunities for growth.

  • Test Types: Analyzes gene panel strategies, laboratory developed tests (LDTs) validated in-house, and liquid biopsy platforms focused on minimally invasive cancer detection.
  • Cancer Types: Examines screening for breast, colorectal, leukemia, lung, non-specific multi-organ, and prostate cancers.
  • Technologies: Details mass spectrometry, microarray, next-generation sequencing, and polymerase chain reaction approaches within screening settings.
  • Payment Sources: Considers government subsidies, out-of-pocket contributions, and private health insurance as market enablers and barriers.
  • Applications: Covers diagnostic screening, individualized risk assessment, patient monitoring, therapy selection, treatment efficacy, and contributions to research pipelines.
  • End Users: Targets adoption among ambulatory surgical centers, diagnostic centers, hospitals, research institutions, and specialty clinics.
  • Regions: Reviews adoption dynamics and segment relevance across Americas, EMEA, and Asia-Pacific, noting local infrastructure capacity and market readiness.

Regional strategies are informed by infrastructure development, evidence requirements, and distinctive payer mechanisms, which together determine optimal product positioning and go-to-market strategies.

Key Takeaways: Strategic Priorities in Multicancer Screening

  • Integrating multicancer screening programs with electronic health records and clinical workflows can streamline adoption and drive meaningful clinical engagement.
  • Clear clinical validation and defined follow-up protocols remain crucial as pilots transition into established medical practice, reinforcing trust among clinicians and patients.
  • Collaborative partnerships between diagnostics developers, laboratories, payers, and patient advocacy groups are central to scaling operations and expanding the market’s population-level impact.
  • Proactive investment in resilient supply chains and procurement flexibility helps secure long-term service reliability amid external disruptions or trade policy changes.
  • Sound ethical practices—especially around incidental findings, consent, and access—help ensure broad patient benefit and compliance across diverse healthcare environments.
  • Adaptive commercial models that align with local payer policies and reimbursement requirements create pathways for sustainable growth in target markets.

Tariff Impact: Supply Chain and Procurement Dynamics

Recent tariff policy changes, particularly in the United States, have significantly impacted the sourcing landscape for essential multicancer screening reagents and test components. These adjustments have raised procurement costs and encouraged laboratories to enhance local supply capacities while renegotiating terms to maintain price stability. Increased focus is now placed on platforms that promise greater consistency of supply. Organizations are adapting through strategic stockpiling, the diversification of vendors, and tailored international partnerships. Scenario planning and risk-sharing contracts have become routine, aiming to secure both research progress and uninterrupted clinical operations despite trade-related volatility.

Methodology & Data Sources

The report is built on a mixed-methods framework, incorporating comprehensive stakeholder interviews, structured literature synthesis, and an in-depth review of global regulatory guidance. Rigorous data extraction, thematic coding, and targeted scenario analyses ensure findings remain robust. Patient protection and data privacy regulations are observed throughout the research process.

Multicancer Screening Market: Why This Report Matters

  • Senior leaders gain a reliable benchmark to inform strategic choices and investments amid changing regulatory and technology ecosystems.
  • Regionally nuanced analysis equips organizations to align operations with local evidence standards and infrastructure developments.
  • Actionable guidance supports improved payer engagement and scalable clinical implementation for wider patient access.

Visual Overview

Conclusion

Multicancer screening continues to progress through integrated innovation, pathway optimization, and focused collaboration. Organizations that align strategy, product development, and evidence generation to active market changes will be best positioned to advance clinical and commercial outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Multicancer Screening Market, by Test Type
8.1. Gene Panel
8.2. Laboratory Developed Test
8.3. Liquid Biopsy
9. Multicancer Screening Market, by Cancer Type
9.1. Breast Cancer
9.2. Colorectal Cancer
9.3. Leukemia
9.4. Lung Cancer
9.5. Non-Specific Multi-Organ Cancer
9.6. Prostate Cancer
10. Multicancer Screening Market, by Technology
10.1. Mass Spectrometry
10.2. Microarray
10.3. Next - Generation Sequencing
10.4. Polymerase Chain Reaction
11. Multicancer Screening Market, by Payment Source
11.1. Government Subsidies
11.2. Out-of-Pocket Payment
11.3. Private Health Insurance
12. Multicancer Screening Market, by Application
12.1. Diagnostic Screening
12.1.1. Early Detection
12.1.2. Risk Assessment
12.2. Prognostics
12.2.1. Patient Monitoring
12.2.2. Therapy Selection
12.2.3. Treatment Efficacy Assessment
12.3. Research Applications
12.3.1. Biomarker Discovery
12.3.2. Genetic Research
13. Multicancer Screening Market, by End User
13.1. Ambulatory Surgical Centers
13.2. Diagnostic Centers
13.3. Hospitals
13.4. Research Institutions
13.5. Specialty Clinics
14. Multicancer Screening Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Multicancer Screening Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Multicancer Screening Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Multicancer Screening Market
18. China Multicancer Screening Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. ANPAC Bio-Medical Science Co., Ltd.
19.6. Burning Rock Biotech Limited
19.7. Caris Life Sciences
19.8. Coyne Medical Ltd.
19.9. Delfi Diagnostics, Inc.
19.10. Elypta AB
19.11. EpiCypher, Inc.
19.12. Epigenomics AG
19.13. Exact Sciences Corporation
19.14. Foundation Medicine, Inc.
19.15. Freenome Holdings, Inc.
19.16. Fulgent Genetics, Inc.
19.17. Gene Solutions
19.18. Grail, LLC by Illumina, Inc.
19.19. Guangzhou AnchorDx Medical Co., Ltd.
19.20. Guardant Health, Inc.
19.21. Invitae Corporation
19.22. Laboratory Corporation of America Holdings
19.23. Lucence Health Inc.
19.24. Micronoma, Inc.
19.25. MiRXES Pte Ltd.
19.26. Myriad Genetics, Inc.
19.27. Natera, Inc.
19.28. Naveris, Inc.
19.29. NeoGenomics Laboratories
19.30. OneTest
19.31. Siemens Healthineers AG
19.32. StageZero Life Sciences. Ltd.
List of Figures
FIGURE 1. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. EUROPE MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 147. EUROPE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 148. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 149. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 150. EUROPE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 151. EUROPE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 152. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 153. EUROPE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 154. EUROPE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 167. AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 168. AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 169. AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 170. AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 171. AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 172. AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 173. AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 174. AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 186. ASEAN MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. ASEAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 188. ASEAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 189. ASEAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 190. ASEAN MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 191. ASEAN MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 192. ASEAN MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 193. ASEAN MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 194. ASEAN MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 195. ASEAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 196. GCC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 197. GCC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 198. GCC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 199. GCC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 200. GCC MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 201. GCC MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 202. GCC MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 203. GCC MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 204. GCC MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 205. GCC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 216. BRICS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. BRICS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 218. BRICS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 219. BRICS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 220. BRICS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 221. BRICS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 222. BRICS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 223. BRICS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 224. BRICS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 225. BRICS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 226. G7 MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 227. G7 MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 228. G7 MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 229. G7 MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 230. G7 MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 231. G7 MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 232. G7 MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 233. G7 MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 234. G7 MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 235. G7 MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. NATO MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 237. NATO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 238. NATO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 239. NATO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 240. NATO MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 241. NATO MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 242. NATO MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 243. NATO MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 244. NATO MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 245. NATO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 246. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 248. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 249. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 251. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 252. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 254. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 255. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 257. CHINA MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 258. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 259. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 260. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 261. CHINA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
TABLE 262. CHINA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 263. CHINA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
TABLE 264. CHINA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
TABLE 265. CHINA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 266. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Multicancer Screening market report include:
  • ANPAC Bio-Medical Science Co., Ltd.
  • Burning Rock Biotech Limited
  • Caris Life Sciences
  • Coyne Medical Ltd.
  • Delfi Diagnostics, Inc.
  • Elypta AB
  • EpiCypher, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Foundation Medicine, Inc.
  • Freenome Holdings, Inc.
  • Fulgent Genetics, Inc.
  • Gene Solutions
  • Grail, LLC by Illumina, Inc.
  • Guangzhou AnchorDx Medical Co., Ltd.
  • Guardant Health, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • Micronoma, Inc.
  • MiRXES Pte Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Naveris, Inc.
  • NeoGenomics Laboratories
  • OneTest
  • Siemens Healthineers AG
  • StageZero Life Sciences. Ltd.

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 822.84 Million
Forecasted Market Value ( USD ) by 2032 $ 4370 Million
Compound Annual Growth Rate31.8%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Multicancer Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Multicancer Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 189 Pages
  • Global
From
Colorectal Cancer Screening and Diagnostics Market - Product Image

Colorectal Cancer Screening and Diagnostics Market

  • Report
  • 166 Pages
  • Global
From
Non-Invasive Cancer Diagnostics Market - Global Strategic Business Report - Product Image

Non-Invasive Cancer Diagnostics Market - Global Strategic Business Report

  • Report
  • 385 Pages
  • Global
From
Next-Generation Breast Cancer Diagnostic & Screening Market - Global Forecast 2026-2032 - Product Image

Next-Generation Breast Cancer Diagnostic & Screening Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Colorectal Cancer Screening & Diagnostic Market - Global Forecast 2026-2032 - Product Image

Colorectal Cancer Screening & Diagnostic Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.